Navigation Links
Drugs for Inflammatory Bowel Might Increase Cancer Risk

Long-term use of thiopurines bears further study, researchers say

MONDAY, Oct. 19 (HealthDay News) -- The use of thiopurine drugs to treat inflammatory bowel disease (IBD) increases the risk of cancers related to viral infection, according to a new study.

IBD includes Crohn's disease and ulcerative colitis. Thiopurine drugs are used to suppress the immune system in order to maintain remission in IBD patients.

For this study, French researchers analyzed data on 19,486 IBD patients (60 percent with Crohn's and 40 percent with ulcerative colitis or unclassified IBD) who were followed for a median of 35 months.

At the start of the study, 30 percent of patients were taking thiopurines, 14 percent had discontinued them, and 56 percent had never received thiopurines. During the study, 23 patients developed malignant lymphoproliferative disorders (LD) -- cancers that are associated with viral infection, particularly those linked to Epstein Barr virus (EBV) infection.

Of the 23 patients with LD, 22 had non-Hodgkin's lymphoma and one had Hodgkin's lymphoma. Incidence rates of LD were 0.90 per 1,000 patient-years in those receiving thiopurines, 0.20 per 1,000 patient-years in those who'd discontinued the drugs, and 0.26 per 1,000 patient-years in those who'd never taken thiopurines.

The researchers calculated that IBD patients taking thiopurines had a more-than-five-fold increased risk compared to those who'd never received the drugs. Older patients, men, and those who'd had IBD for longer were also at increased risk of LD.

"Extrapolating our results, the absolute cumulative risk of (LD) in young patients receiving a 10-year course of thiopurines remains low (less than 1 percent) and does not undermine the positive risk-benefit ratio of these drugs. For elderly patients and unlimited treatment periods, the question should be addressed in dedicated studies," wrote Laurent Beaugerie, a professor at Hospital Saint-Antoine, Paris, and colleagues.

The study appeared online Monday and in an upcoming print issue of The Lancet.

"Although we recognize the slightly increased risk of lymphoma, these agents will probably remain one of the cornerstones of treatment. Nonetheless, physicians should be cautious when prolonged combined and deep immunosuppression is needed to achieve disease control," Dr. Geert D'Haens, of the Imelda GI Clinical Research Centre and University Hospital Gasthuisberg in Belgium, and Dr. Paul Rutgeerts, University Hospital Gasthuisberg, wrote in an accompanying editorial.

More information

The Crohn's and Colitis Foundation of America has more about IBD.

-- Robert Preidt

SOURCE: The Lancet, news release, Oct. 18, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Drugs for Irritable Bowel Might Increase Cancer Risk
2. Pitt researchers find candidates for new HIV drugs
3. Designing drugs and their antidotes together improves patient care
4. Risk of abnormally slow heart rate twice as high in those taking drugs to slow Alzheimers
5. Teen attitudes toward smoking linked to likelihood of drinking and using drugs
6. UCLA study identifies 2 chemicals that could lead to new drugs for genetic disorders
7. GENova Biotherapeutics secures new cancer drugs targets
8. Reportlinker Adds World Anti-Obesity Drugs Market Report
9. Yeast unravels effects of chemotherapy drugs
10. Vitro's Cancer Stem Cell Therapy Complements New Hedge Hog Drugs
11. Antiviral Drugs Should Be Used Cautiously to Fight Flu, U.S. Says
Post Your Comments:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: